Biologic Principles of Immunotherapy for Malignant Gliomas

Neurosurgery Clinics of North America

Volumn 21, Issue 1, 2010, Pages 1-16

  Han, Seunggu J ^a   Kaur, Gurvinder ^a   Yang, Isaac ^a   Lim, Michael ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glioma; Immunosuppression; Immunotherapy; Tumor specific antigen

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; COMPLEMENTARY DNA; DENDRITIC CELL VACCINE; EMD 55900; EMD 55900 I 125; EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY I 131; INTERLEUKIN 13 RECEPTOR PLUS PSEUDOMONAS EXOTOXIN; INTERLEUKIN 4 PLUS PSEUDOMONAS EXOTOXIN; MODIFIED VACCINIA VIRUS ANKARA VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 81C6 I 131; NIMOTUZUMAB; PEPTIDE VACCINE; PSEUDOMONAS EXOTOXIN PLUS TRANSFORMING GROWTH FACTOR ALPHA; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT CYTOKINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; BLOOD TOXICITY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG CYTOTOXICITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOCYTIC INFILTRATION; LYMPHOKINE ACTIVATED KILLER CELL; NEUROSURGERY; NEUROTOXICITY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

BRAIN; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOTHERAPY;

EID: 70450173710     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2009.08.001     Document Type: Review

References (201)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 10 (2005) 987-996
2. Pardoll D., and Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 10 (2004) 887-892
3. Medawar P. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29 1 (1948) 58-69
4. Cserr H.F., and Knopf P.M. Cervical lymphatics, the blood-brain barrier, and the immunoreactivity of the brain. In: Keane R.W., and Hickey W.F. (Eds). Immunology of the nervous system (1997), Oxford University Press, New York 134-152
5. Lampson L., and Hickey W.F. Monoclonal antibody analysis of MHC expression in human brain biopsies. Tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. J Immunol 136 (1986) 4052-4062
6. Yang I., Kremen T.J., Giovannone A.J., et al. Modulation of major histocompatibility complex class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg 100 2 (2004) 310-319
7. Levi-Strauss M., and Mallat M. Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. J Immunol 139 (1987) 2361-2366
8. Bernheimer H., Lassmann H., and Suchanek G. Dynamics of IgG+, IgA+, and IgM+ plasma cells in the central nervous system of guinea pigs with chronic relapsing experimental allergic encephalomyelitis. Neuropathol Appl Neurobiol 14 (1988) 157-167
9. Sandberg-Wollheim M., Zweiman B., Levinson A.I., et al. Humoral immune responses within the human central nervous system following systemic immunization. J Neuroimmunol 11 3 (1986) 205-214
10. Aloisi F., Ria F., Columba-Cabezas S., et al. Relative efficiency of microglia, astrocytes, dendritic cells and B cells in naive CD4+ T cell priming and Th1/Th2 cell restimulation. Eur J Immunol 29 9 (1999) 2705-2714
11. Aloisi F., Ria F., Penna G., et al. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J Immunol 160 10 (1998) 4671-4680
12. Brannan C.A., and Roberts M.R. Resident microglia from adult mice are refractory to nitric oxide-inducing stimuli due to impaired NOS2 gene expression. Glia 48 2 (2004) 120-131
13. Hickey W.F., and Kimura H. Graft-vs-host disease elicits expression of class I and class II histocompatibility antigens and the presence of scattered T lymphocytes in rat central nervous system. Proc Natl Acad Sci U S A 84 7 (1987) 2082-2086
14. Krakowski M., and Owens T. Naive T lymphocytes traffic to inflamed central nervous system, but require antigen recognition for activation. Eur J Immunol 60 (2000) 5731-5739
15. Hickey W.F., Hsu B.L., and Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 28 2 (1991) 254-260
16. Hickey W.F. Basic principles of immunological surveillance of the normal central nervous system. Glia 36 2 (2001) 118-124
17. Sampson J., Archer G.E., Ashley D.M., et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A 93 19 (1996) 10399-10404
18. Gordon L.B., Nolan S.C., Cserr H.F., et al. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity. J Immunol 159 5 (1997) 2399-2408
19. Badie B., Schartner J.M., Paul J., et al. Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg 93 4 (2000) 634-639
20. Sawamura Y., Hosokawa M., Kuppner M.C., et al. Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2. Cancer Res 49 7 (1989) 1843-1849
21. Das S., Raizer J.J., and Muro K. Immunotherapeutic treatment strategies for primary brain tumors. Curr Treat Options Oncol 9 1 (2008) 32-40
22. Parney I., Hao C., and Petruk K. Glioma immunology and immunotherapy. Neurosurgery 46 4 (2000) 778-791
23. Facoetti A., Nano R., Zelini P., et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 11 23 (2005) 8304-8311
24. Parney I.F., Waldron J.S., and Parsa A.T. Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J Neurosurg 110 3 (2009) 572-582
25. Flugel A., Labeur M.S., Grasbon-Frodi E.M., et al. Microglia only weakly present glioma antigen to cytotoxic T cells. Int J Dev Neurosci 17 5-6 (1999) 547-556
26. Schartner J.M., Hagar A.R., Van Handel M., et al. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 51 4 (2005) 279-285
27. Kostianovsky A.M., Maier L.M., Anderson R.C., et al. Astrocytic regulation of human monocytic/microglial activation. J Immunol 181 8 (2008) 5425-5432
28. Roszman T.L., and Brooks W.H. Neural modulation of immune function. J Neuroimmunol 10 1 (1985) 59-69
29. Roszman T.L., Brooks W.H., Steele C., et al. Pokeweed mitogen-induced immunoglobulin secretion by peripheral blood lymphocytes from patients with primary intracranial tumors. Characterization of T helper and B cell function. J Immunol 134 3 (1985) 1545-1550
30. Elliott L.H., Brooks W.H., and Roszman T.L. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J Immunol 132 3 (1984) 1208-1215
31. Brooks W.H., Markesbery W.R., Gupta G.D., et al. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 4 3 (1978) 219-224
32. Palma L., Di Lorenzo N., and Guidetti B. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J Neurosurg 49 6 (1978) 854-861
33. Dunn G.P., Dunn I.F., and Curry W.T. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 7 (2007) 12
34. Safdari H., Hochberg F.H., and Richardson Jr. E.P. Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas. Surg Neurol 23 3 (1985) 221-226
35. Hussain S.F., and Heimberger A.B. Immunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther 5 5 (2005) 777-790
36. Gerosa M.A., Olivi A., Rosenblum M.L., et al. Impaired immunocompetence in patients with malignant gliomas: the possible role of Tg-lymphocyte subpopulations. Neurosurgery 10 5 (1982) 571-573
37. El Andaloussi A., and Lesniak M.S. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 8 3 (2006) 234-243
38. Fecci P.E., Mitchell D.A., Whitesides J.F., et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66 6 (2006) 3294-3302
39. Thornton A.M., and Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188 2 (1998) 287-296
40. Camara N.O., Sebille F., and Lechler R.I. Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol 33 12 (2003) 3473-3483
41. Piccirillo C.A., and Shevach E.M. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167 3 (2001) 1137-1140
42. Dieckmann D., Bruett C.H., Ploettner H., et al. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. [corrected]. J Exp Med 196 2 (2002) 247-253
43. Liu V.C., Wong L.Y., Jang T., et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178 5 (2007) 2883-2892
44. Zheng Y., Manzotti C.N., Liu M., et al. CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J Immunol 172 5 (2004) 2778-2784
45. Fecci P.E., Sweeney A.E., Grossi P.M., et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 12 14 Pt 1 (2006) 4294-4305
46. El Andaloussi A., Han Y., and Lesniak M.S. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 105 3 (2006) 430-437
47. Nitta T., Hishii M., Sato K., et al. Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 649 1-2 (1994) 122-128
48. Fontana A., Kristensen F., Dubs R., et al. Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol 129 6 (1982) 2413-2419
49. Sawamura Y., Diserens A.C., and de Tribolet N. In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes. J Neurooncol 9 2 (1990) 125-130
50. Couldwell W.T., Yong V.W., Dore-Duffy P., et al. Production of soluble autocrine inhibitory factors by human glioma cell lines. J Neurol Sci 110 1-2 (1992) 178-185
51. Dix A., Brooks W.H., Roszman T.L., et al. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100 1-2 (1999) 216-232
52. Bodmer S., Strommer K., Frei K., et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143 10 (1989) 3222-3229
53. Fontana A., Hengartner H., de Tribolet N., et al. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 132 4 (1984) 1837-1844
54. Fontana A., Frei K., Bodmer S., et al. Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol 143 10 (1989) 3230-3234
55. Suzumura A., Sawada M., Yamamoto H., et al. Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro. J Immunol 151 4 (1993) 2150-2158
56. Liau L., Fakhrai H., and Black K. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurol Res 20 8 (1998) 742-747
57. Fakhrai H., Dorigo O., Shawler D.L., et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A 93 7 (1996) 2909-2914
58. Yang B.C., Lin H.K., Hor W.S., et al. Mediation of enhanced transcription of the IL-10 gene in T cells, upon contact with human glioma cells, by Fas signaling through a protein kinase A-independent pathway. J Immunol 171 8 (2003) 3947-3954
59. Parsa A.T., Waldron J.S., Panner A., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13 1 (2007) 84-88
60. Ichinose M., Masuoka J., Shiraishi T., et al. Fas ligand expression and depletion of T-cell infiltration in astrocytic tumors. Brain Tumor Pathol 18 1 (2001) 37-42
61. Hahn H.P., Pang M., He J., et al. Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death. Cell Death Differ 11 12 (2004) 1277-1286
62. Rorive S., Belot N., Decaestecker C., et al. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 33 3 (2001) 241-255
63. Badie B., Schartner J., Prabakaran S., et al. Expression of Fas ligand by microglia: possible role in glioma immune evasion. J Neuroimmunol 120 1-2 (2001) 19-24
64. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8 8 (2002) 793-800
65. Magnus T., Schreiner B., Korn T., et al. Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci 25 10 (2005) 2537-2546
66. Barshes N.R., Goodpastor S.E., and Goss J.A. Pharmacologic immunosuppression. Front Biosci 9 (2004) 411-420
67. Lesniak M.S., Gabikian P., Tyler B.M., et al. Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors. J Neurooncol 70 1 (2004) 23-28
68. Su Y.B., Sohn S., Krown S.E., et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22 4 (2004) 610-616
69. Kikuchi T., Joki T., Abe T., et al. Antitumor activity of killer cells stimulated with both interleukin-2 and interleukin-12 on mouse glioma cells. J Immunother 22 3 (1999) 245-250
70. Jereb B., Petric J., Lamovec J., et al. Intratumor application of human leukocyte interferon-alpha in patients with malignant brain tumors. Am J Clin Oncol 12 1 (1989) 1-7
71. Farkkila M., Jaaskelainen J., Kallio M., et al. Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 70 1 (1994) 138-141
72. Merchant R.E., McVicar D.W., Merchant L.H., et al. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial. J Neurooncol 12 1 (1992) 75-83
73. Buckner J.C., Schomberg P.J., McGinnis W.L., et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 92 2 (2001) 420-433
74. Chamberlain M.C. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer 94 10 (2002) 2675-2680
75. Liu Y., Ehtesham M., Samoto K., et al. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther 9 1 (2002) 9-15
76. Ren H., Boulikas T., Lundstrom K., et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene-a phase I/II clinical protocol. J Neurooncol 64 1-2 (2003) 147-154
77. Ehtesham M., Samoto K., Kabos P., et al. Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer. Cancer Gene Ther 9 11 (2002) 925-934
78. Lichtor T., Glick R.P., Kim T.S., et al. Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 83 (1995) 1038-1044
79. Lichtor T., Glick R.P., Tarlock K., et al. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 9 5 (2002) 464-469
80. Glick R.P., Lichtor T., Panchal R., et al. Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors. J Neurooncol 64 1-2 (2003) 139-146
81. Kikuchi T., Joki T., Saitoh S., et al. Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system. Int J Cancer 80 3 (1999) 425-430
82. Benedetti S., Pirola B., Pollo B., et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 6 4 (2000) 447-450
83. Ehtesham M., Kabos P., Kabosova A., et al. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 62 20 (2002) 5657-5663
84. Yuan X., Hu J., Belladonna M.L., et al. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res 66 5 (2006) 2630-2638
85. Mizuno M., and Yoshida J. Effect of human interferon beta gene transfer upon human glioma, transplanted into nude mouse brain, involves induced natural killer cells. Cancer Immunol Immunother 47 4 (1998) 227-232
86. Natsume A., Mizuno M., Ryuke Y., et al. Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther 6 9 (1999) 1626-1633
87. Natsume A., Tsujimura K., Mizuno M., et al. IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol 47 2 (2000) 117-124
88. Rhines L.D., Sampath P., DiMeco F., et al. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery 52 4 (2003) 872-879 [discussion: 879-80]
89. Hanes J., Sills A., Zhao Z., et al. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 18 7 (2001) 899-906
90. Hsu W., Lesniak M.S., Tyler B., et al. Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma. J Neurooncol 74 2 (2005) 135-140
91. Puri R.K., Leland P., Kreitman R.J., et al. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer 58 4 (1994) 574-581
92. Joshi B.H., Leland P., Asher A., et al. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res 61 22 (2001) 8058-8061
93. Joshi B.H., Leland P., Silber J., et al. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein. Br J Cancer 86 2 (2002) 285-291
94. Rand R.W., Kreitman R.J., Patronas N., et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6 6 (2000) 2157-2165
95. Weber F.W., Floeth F., Asher A., et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 88 (2003) 93-103
96. Weber F., Asher A., Bucholz R., et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64 1-2 (2003) 125-137
97. Kioi M., Kawakami K., and Puri R.K. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin. Clin Cancer Res 10 18 Pt 1 (2004) 6231-6238
98. Joshi B.H., Leland P., and Puri R.K. Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-pseudomonas exotoxin fusion protein. Croat Med J 44 4 (2003) 455-462
99. Husain S.R., Joshi B.H., and Puri R.K. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 92 2 (2001) 168-175
100. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 88 (2003) 105-111
101. Kunwar S., Prados M.D., Chang S.M., et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25 7 (2007) 837-844
102. Parney I.F., Kunwar S., McDermott M., et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 102 2 (2005) 267-275
103. Kioi M., Seetharam S., and Puri R.K. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther 7 6 (2008) 1579-1587
104. Vogelbaum M.A., Sampson J.H., Kunwar S., et al. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 61 5 (2007) 1031-1037 [discussion: 1037-8]
105. Heimbrook D.C., Stirdivant S.M., Ahern J.D., et al. Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts. Proc Natl Acad Sci U S A 87 12 (1990) 4697-4701
106. Phillips P.C., Levow C., Catterall M., et al. Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res 54 4 (1994) 1008-1015
107. Sampson J.H., Akabani G., Archer G.E., et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65 1 (2003) 27-35
108. Sampath P., Hanes J., DiMeco F., et al. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res 59 9 (1999) 2107-2114
109. Hopkins K., Papanastassiou V., and Kemshead J.T. The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates. Recent Results Cancer Res 141 (1996) 159-175
110. Prasad G., Wang H., Hill D.L., et al. Recent advances in experimental molecular therapeutics for malignant gliomas. Curr Med Chem Anticancer Agents 4 4 (2004) 347-361
111. Bourdon M.A., Wikstrand C.J., Furthmayr H., et al. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 43 6 (1983) 2796-2805
112. 131I-labeled antitenascin monoclonal antibody 81C6. Cancer Res 48 10 (1988) 2904-2910
113. 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res 48 3 (1988) 559-566
114. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49 10 (1989) 2807-2813
115. Bigner D.D., Brown M.T., Friedman A.H., et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 16 6 (1998) 2202-2212
116. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 2 6 (1996) 963-972
117. Riva P., Fraceschi G., Arista A., et al. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer 80 Suppl 12 (1997) 2733-2742
118. Akabani G., Cokgor I., Coleman R.E., et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys 46 4 (2000) 947-958
119. Reardon D.A., Akabani G., Coleman R.E., et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 24 1 (2006) 115-122
120. 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 46 6 (2005) 1042-1051
121. Reardon D.A., Akabani G., Coleman R.E., et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20 5 (2002) 1389-1397
122. Cokgor I., Akabani G., Kuan C.T., et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18 22 (2000) 3862-3872
123. 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med 47 6 (2006) 912-918
124. Kalofonos H.P., Pawikowska T.R., Hemingway A., et al. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 30 10 (1989) 1636-1645
125. Dadparvar S., Krishna L., Miyamoto C., et al. Indium-111-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas. Cancer 73 Suppl 3 (1994) 884-889
126. Faillot T., Magdelenat H., Mady E., et al. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery 39 3 (1996) 478-483
127. Crombet T., Torres O., Neninger E., et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother Radiopharm 16 1 (2001) 93-102
128. Stragliotto G., Vega F., Stasiecki P., et al. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer 32 4 (1996) 636-640
129. Wersall P., Ohlsson I., Biberfeld P., et al. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother 44 3 (1997) 157-164
130. Ramos T.C., Figueredo J., Catala M., et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 5 4 (2006) 375-379
131. Brady L.W. A new treatment for high grade gliomas of the brain. Bull Mem Acad R Med Belg 153 5-6 (1998) 255-261 [discussion: 261-2]
132. Brady L.W., Markoe A.M., Woo D.V., et al. Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. A pilot study. Front Radiat Ther Oncol 24 (1990) 151-160 [discussion: 161-5]
133. Brady L.W., Miyamoto C., Woo D.V., et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 22 1 (1992) 225-230
134. Snelling L., Miyamoto C.T., Bender H., et al. Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma 14 2 (1995) 111-114
135. Jungbluth A.A., Stockert E., Huang J.H., et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A 100 2 (2003) 639-644
136. Sampson J.H., Crotty L.E., Lee S., et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 97 13 (2000) 7503-7508
137. Mishima K., Johns T.G., Luwor R.B., et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61 14 (2001) 5349-5354
138. Mamot C., Drummond D.C., Greiser U., et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 63 12 (2003) 3154-3161
139. Mamot C., Drummond D.C., Noble C.O., et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65 24 (2005) 11631-11638
140. Hall W.A. Targeted toxin therapy for malignant astrocytoma. Neurosurgery 46 3 (2000) 544-551 [discussion: 552]
141. Jacobs S.K., Wilson S.K., Kronblith P.L., et al. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg 64 5 (1986) 743-749
142. Merchant R.E., Grant A.J., Merchant L.H., et al. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 62 4 (1988) 665-671
143. Merchant R.E., Merchant L.H., Cook S.H., et al. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23 6 (1988) 725-732
144. Barba D., Saris S.C., Holder C., et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70 2 (1989) 175-182
145. Lillehei K.O., Mitchell D.H., Johnson S.D., et al. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28 1 (1991) 16-23
146. Hayes R.L., Koslow M., Hiesiger E.M., et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76 5 (1995) 840-852
147. Dillman R.O., Duman C.M., Schiltz P.M., et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27 5 (2004) 398-404
148. Nitta T., Sato K., Okumura K., et al. Induction of cytotoxicity in human T cells coated with anti-glioma x anti-CD3 bispecific antibody against human glioma cells. J Neurosurg 72 3 (1990) 476-481
149. Nitta T., Sato K., Yagita H., et al. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335 8686 (1990) 368-371
150. Tsurushima H., Lui S.Q., Tsuboi K., et al. Induction of human autologous cytotoxic T lymphocytes against minced tissues of glioblastoma multiforme. J Neurosurg 84 2 (1996) 258-263
151. Saris S.C., Spiess P., Lieberman D.M., et al. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 76 3 (1992) 513-519
152. Holladay F.P., Heitz T., and Wood G.W. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. J Neurosurg 77 5 (1992) 757-762
153. Holladay F.P., Hetiz T., Chen Y.L., et al. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery 31 3 (1992) 528-533
154. Holladay F., Heitz T., Wood G.W., et al. Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. J Neuro oncol 27 2 (1996) 179-189
155. Quattrocchi K.B., Miller C.H., Cush S., et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 45 2 (1999) 141-157
156. Miescher S., Stoeck M., Whiteside T.L., et al. Altered activation pathways in T lymphocytes infiltrating human solid tumors. Transplant Proc 20 2 (1988) 344-346
157. Miescher S., Whiteside T.L., de Tribolet N., et al. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 68 3 (1988) 438-448
158. Roszman T., Elliott L., and Brooks W. Modulation of T-cell function by gliomas. Immunol Today 12 10 (1991) 370-374
159. Prins R.M., Graf M.R., and Merchant R.E. Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis. Cancer Immunol Immunother 50 6 (2001) 285-292
160. Plautz G., Barnett G.H., Miller D.W., et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 89 1 (1998) 42-51
161. Plautz G.E., Miller D.W., Barnett G.H., et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6 6 (2000) 2209-2218
162. Cesano A., Visonneau S., and Santoli D. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line. Cancer Res 55 1 (1995) 96-101
163. Cesano A., Visonneau S., and Santoli D. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice. Anticancer Res 18 4A (1998) 2289-2295
164. Cesano A., Visonneau S., Pasquini S., et al. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia. Cancer Res 56 19 (1996) 4444-4452
165. Geoerger B., Tang C.B., Cesano A., et al. Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts. Neuro Oncol 2 2 (2000) 103-113
166. Kruse C.A., Visonneau S., Kleinschmidt-DeMasters B.K., et al. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy. Cancer Res 60 20 (2000) 5731-5739
167. Gomez G.G., Read S.B., Gerschenson L.E., et al. Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors. Neuro Oncol 6 2 (2004) 83-95
168. Brando C., Mukhopadhyay S., Kovacs E., et al. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104. J Leukoc Biol 78 2 (2005) 359-371
169. Wikstrand C.J., and Bigner D.D. Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha. J Natl Cancer Inst 90 11 (1998) 799-801
170. Lozupone F., Rivoltini L., Luciani F., et al. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J Immunol 33 2 (2003) 556-566
171. Steiner H.H., Bonsanto M.M., Beckhove P., et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 22 21 (2004) 4272-4281
172. Sloan A.E., Dansey R., Zamorano L., et al. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 9 6 (2000) e9
173. Ishikawa E., Tsuboi K., Yamamoto T., et al. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci 98 8 (2007) 1226-1233
174. Okada H., Lieberman F.S., Walter K.A., et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 5 (2007) 67
175. Thurner B., Roder C., Dieckmann D., et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223 1 (1999) 1-15
176. Siesjö P., Visse E., and Sjögren H. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Emphasis Tumor Immunol 19 5 (1996) 334-345
177. Liau L., Black K.L., Prins R.M., et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90 6 (1999) 1115-1124
178. Yu J.S., Wheeler C.J., Zeltzer P.M., et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61 3 (2001) 842-847
179. Kikuchi T., Akasaki Y., Irie M., et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50 7 (2001) 337-344
180. Kikuchi T., Akasaki Y., Abe T., et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27 6 (2004) 452-459
181. Kjaergaard J., Wang L.X., Kuriyama H., et al. Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg 103 1 (2005) 156-164
182. Yu J.S., Lui G., Ying H., et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64 14 (2004) 4973-4979
183. Yamanaka R., Abe T., Yajima N., et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89 7 (2003) 1172-1179
184. Rutkowski S., De Vleeschouwer S., Kaempgen E., et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91 9 (2004) 1656-1662
185. Liau L.M., Prins R.M., Kierscher S.M., et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11 15 (2005) 5515-5525
186. Ludewig B., Oschesenbein A.F., Odermatt B., et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 191 5 (2000) 795-804
187. Wu A.H., Xiao J., Anker L., et al. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol 76 1 (2006) 23-30
188. Heimberger A.B., Archer G.E., Crotty L.E., et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50 1 (2002) 158-164 [discussion 164-6]
189. Heimberger A.B., Crotty L.E., Archer G.E., et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9 11 (2003) 4247-4254
190. Wood G.W., Holladay F.P., Turner T., et al. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol 48 2 (2000) 113-120
191. Liau L.M., Jensen E.R., Kremen T.J., et al. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res 62 8 (2002) 2287-2293
192. Brockstedt D.G., Giedlin M.A., Leong M.L., et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A 101 38 (2004) 13832-13837
193. Meyer R.G., Britten C.M., Siepmann U., et al. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother 54 5 (2005) 453-467
194. Yang L., Ng K.Y., and Lillehei K.O. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 10 2 (2003) 138-147
195. Kuwashima N., Nishimura F., Eguchi J., et al. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol 175 4 (2005) 2730-2740
196. Okada H., Pollack I.F., Lieberman F., et al. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum Gene Ther 12 5 (2001) 575-595
197. Yamanaka R., Honma J., Tsuchiya N., et al. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. J Neurooncol 72 2 (2005) 107-113
198. Kikuchi T., et al. Antitumor activity of interleukin 12 against interleukin 2-transduced mouse glioma cells. Cancer Lett 135 1 (1999) 47-51
199. Parney I.F., Petruk K.C., Zhang C., et al. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum Gene Ther 8 9 (1997) 1073-1085
200. Saleh M., Jonas N.K., Wiegmans A., et al. The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer. Gene Ther 7 20 (2000) 1715-1724
201. Benedetti S., Bruzzone M.G., Pollo B., et al. Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene. Cancer Res 59 3 (1999) 645-652